about
Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial diseaseNatural language processor as a tool to assess heparin induced thrombocytopenia awareness.Adrenal haemorrhage due to heparin-induced thrombocytopenia.The association of active cancer with venous thromboembolism location: a population-based study.Outcomes of venoplasty with stent placement for chronic thrombosis of the iliac and femoral veins: single-center experiencePlatelet activation and its patient-specific consequences.Acquired and congenital risk factors associated with cerebral venous sinus thrombosis.The role of novel anticoagulants in the management of venous thromboembolic disease.Antiphospholipid antibodies in thromboangiitis obliterans.Images in vascular medicine. Fibromuscular dysplasia: an atypical cause of intermittent claudication.Individual propensity for thrombosis: comparison of venous and arterial circulations.Predicting left atrial thrombi in atrial fibrillation.Periprocedural anticoagulation management of patients with venous thromboembolism.Survival and recurrence in patients with splanchnic vein thromboses.Inhibition of platelet-rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMG-CoA reductase therapy.Outcomes and total costs of outpatient vs. inpatient peri-procedural anticoagulation management of mechanical prosthetic heart valve patients.Thrombophilia differences in splanchnic vein thrombosis and lower extremity deep venous thrombosis in North America.Pneumatic compression for embolic protection during upper extremity endovascular intervention.Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi.Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation.Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: Response to warfarin.Clinical characteristics and long-term follow-up of patients with renal vein thrombosis.Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct Factor Xa inhibitor, compared with antiplatelet agents in pigs.Fibrin d-dimer concentration, deep vein thrombosis symptom duration, and venous thrombus volume.Impact of atrial fibrillation on platelet gene expression.Platelet-predominate gene expression and reticulated platelets in non-valvular atrial fibrillation: Effect of pulmonary veins isolation.Effect of atrial fibrillation duration on plasma von Willebrand factor level.Testicular vein thrombosis: Incidence of recurrent venous thromboembolism and survival.Lupus anticoagulant, warfarin, and alternative laboratory monitoring of anticoagulation.Platelet recruitment to venous stent thrombi.Platelet factor XIII gene expression and embolic propensity in atrial fibrillation.Propensity for young reticulated platelet recruitment into arterial thrombiThree-month cumulative incidence of thromboembolism and bleeding after periprocedural anticoagulation management of arterial vascular bypass patientsCancer effect on periprocedural thromboembolism and bleeding in anticoagulated patientsPeriprocedural Bridging Management of AnticoagulationPredictors of major bleeding in peri-procedural anticoagulation managementSeptic venous thromboembolismLeft Atrial Blood Stasis and Von Willebrand Factor–ADAMTS13 Homeostasis in Atrial FibrillationBudd-Chiari syndrome, mediastinal mass and recalcitrant leg ulcers, an unlikely trioClinical and echocardiographic measures governing thromboembolism destination in atrial fibrillation
P50
Q28217451-80CD6F0B-A276-43F8-9E95-67CC6C32841DQ33396823-2E18FBA4-300D-4835-9595-9D9A55300556Q33405730-DF458952-009F-4F39-A4EF-F50FCE180D02Q34450928-4A5BCDC1-2CF2-4B72-9C28-01FF13B13112Q36136618-971363F0-C0ED-4BA1-B35B-7B248F8A6134Q36976150-82E4C87B-537F-47ED-BDDE-EF8F3C049429Q37764456-B1FB7123-CBFF-42BE-83C0-FED21E9C3ADBQ38218874-4CDF7A06-DA68-4DF9-9918-60A4DF88A4AEQ39647780-50672AB0-6848-4348-A148-C3F4223DCE0CQ39706491-88473FE4-EF0C-4811-9757-FA31E8620B29Q42521917-754C49C9-A324-43DC-9E8A-297543C8C6BCQ43110688-DE3515AB-F93E-4028-9254-CB1A193DD2DAQ43170024-24D09937-9407-45D2-95E4-3C532711FB1DQ43270848-9CD252FD-DF23-4479-865B-0F0C0573802BQ43295167-67A5CC77-2596-4F2E-B33E-0EC064F8C2B7Q44124168-660C22C5-7CEF-4AC3-8C55-AFF163753A29Q44247861-C908C8B4-BF25-4538-BBC2-30D45D66CBC8Q44720746-41D4F2FF-C839-4226-812E-6F6683FC5C64Q45033738-FC6EAF61-5A4D-44F7-B2BB-FEC17A84A325Q46557263-FE9BFF34-1ABB-46DB-89FE-CCA3566DCE1AQ46749428-70F74441-DA9F-4BED-BFD5-9AD59F1A6324Q46794213-6A0864C2-82E7-48E2-9284-ECAE4FED9984Q46838356-F505F22F-BDBA-4548-B550-490BDBC8E473Q47362086-92F7D545-A7EC-4161-874F-FFDB3C16011DQ48110678-80CCF8D6-CAAB-4872-A996-09DE9A448054Q48151431-50891F7F-DB8C-4B28-9B88-D6E1B2CD45DBQ48283061-13AD3E90-48D3-4F84-AF29-1C192EACD0B9Q48316812-D8C94FDE-0F29-489B-8029-EC67E00A9F80Q50929892-83EEA157-57B2-4995-A06B-42FF1BE189EFQ51063246-EC28D597-8EAF-4EF6-98DA-FC33F70661AAQ51165348-8AF9FAA6-827B-4B7A-A2E6-DAEF3A264E0EQ57907783-3B89DD50-14C5-4581-8282-E3C49328CF52Q57907819-F55B9B1F-3B29-4EBB-81E6-3718DBFF1CDEQ57907829-F39FD7DA-D8CA-4CB2-BC5D-BBD164EC16BCQ57907844-9CA3B546-9ACA-4431-97A7-154B54DBA1BCQ57907851-1E15CC8D-F0E3-4392-9197-BAFE071E567DQ57907856-ECF09B0B-AFDD-48BC-BC9A-102622122360Q57907863-9E130AC4-94D6-4C3F-9B38-559ECB66D992Q57907872-5029F2E1-EBE8-4738-8590-40E6CE7C3EAFQ57907893-6C9AF0AC-441D-4A16-A145-BD9E3D846CC4
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Waldemar E. Wysokinski
@ast
Waldemar E. Wysokinski
@en
Waldemar E. Wysokinski
@es
Waldemar E. Wysokinski
@nl
Waldemar E. Wysokinski
@sl
type
label
Waldemar E. Wysokinski
@ast
Waldemar E. Wysokinski
@en
Waldemar E. Wysokinski
@es
Waldemar E. Wysokinski
@nl
Waldemar E. Wysokinski
@sl
prefLabel
Waldemar E. Wysokinski
@ast
Waldemar E. Wysokinski
@en
Waldemar E. Wysokinski
@es
Waldemar E. Wysokinski
@nl
Waldemar E. Wysokinski
@sl
P106
P1153
6701780067
P21
P31
P496
0000-0002-8119-6206